ResMed beats quarterly profit estimates on demand for sleep disorder devices
ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder. ResMed makes continuous positive ...
Why Weight-Loss Drugs Could Be Game-Changers for Your Investment Portfolio
Weight-loss drugs are transforming both health care and Wall Street, with leading manufacturers like Eli Lilly & Co. (LLY) ...
Yahoo Finance5h
Metsera, Maze secure combined $415 million in IPOs
The company officially emerged from stealth last April. In January, Metsera revealed Phase 2 data suggesting its top prospect ...
Chelsearecord.com6h
GLP-1 Weight-loss Drugs Should be Made Affordable for all Americans
The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...
RFK Jr. hails GLP-1 weight loss meds as 'miracle drugs'
Robert F. Kennedy Jr., President Trump's nominee to lead HHS, spoke highly of GLP-1 drugs at a Senate confirmation hearing ...
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...